Antibiotic Research UK is run by the Trustees (Chairman Mr Ashley Burgess), who are elected by the members.
The Scientific & Technical Advisory Committee is chaired by Dr David Brown and the Chief Executive is Professor Colin Garner.
Members of the Finance Raising and Scientific Advisory Committee are currently in the process of being appointed.
The organisational structure of the Charity is shown in this diagram.
help us save modern medicine!
Meet the Board of Trustees
(Chairman, Board of Trustees)
Ashley Burgess is a Yorkshire based business man and is the founding Director and current Chairman of the family Burgess Group plc and a founding Director of Criddle Burgess Feeds Ltd and Burgess Diagnostic Veterinary Holdings Ltd. He has been Chairman of Scarborough and North East Yorkshire NHS Trust, Scarborough and Ryedale Macmillan Nurse Appeal, Ocean Youth Trust North and Governor Merchant Adventurers City of York.
He is currently a member of Court University of York where he was awarded the Morrell Fellowship in 2008 and has funded two RNLI lifeboats based in Walmer and Cleethorpes and is an RNLI life governor.
He supports an annual PhD studentship in the Department of Biology, University of York. Ashley has a keen interest in the problem of antibiotic resistance and believes that we need to act now to tackle this major health problem.
Professor Colin Garner
BPharm PhD DSc FRCPath (Chief Executive)
Colin Garner is both a university academic scientist and scientific entrepreneur. He graduated from Chelsea College, University of London (now Kings College) and did his PhD in biochemical toxicology at University College Hospital Medical School. After a two year postdoctoral fellowship at the University of Wisconsin, USA he returned to the UK to carry out cancer research at the University of Leeds and then for the majority of his career at the University of York. He headed up a cancer research laboratory for almost 20 years in which time he published over 200 scientific papers and 30 book chapters on the role of gene-environment interactions in cancer causation. Along with two surgeon colleagues, he created the York cancer charity York Against Cancer which provides funds for education, research and patient support.
Colin has founded three university spinout companies and is the founder of Antibiotic Research UK. He believe passionately in the new charity and says ‘there is an urgent need to develop new drugs to tackle antibiotic resistant infections. Antibiotic Research UK as a charity can make a substantial impact as it is a non-profit organisation. The Charity is working with some of the world’s experts in antibiotic resistance to reach its goal’. Colin was an Honorary Professor of Pharmacology at the Hull York Medical School, University of York.
Dr David Brown
BSc PhD FRSC (Chairman, Scientific & Technical Advisory Committee)
Dr David Brown has over 30 years’ experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 Pharma companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche; and also as President and Chief Executive of Cellzome AG, a biotechnology company headquartered in Heidelberg Germany. Whilst at Pfizer he was named co-inventor on the patent for Viagra, a treatment for male impotence, and he led the team that developed Viagra through to proof of clinical efficacy in human clinical trials. The active ingredient sildenafil is also used to treat pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have sales > $30 billion. While at Roche in Switzerland, he was a Director of the company and had responsibility for productivity of over 2000 staff focused on drug discovery at all six of Roche’s research sites in the USA, Europe and Asia. He also served on Clinical Development and Business Development senior committees.
Since 2005 Dr Brown has pursued a portfolio of roles dedicated to bringing new medical treatments to both the developed and developing world. He has been heavily involved with OneWorld Health, San Francisco, (now called PATH Drug Solutions) where his work, and that of the organization, is dedicated to bringing medicines to the poorest of the poor in the world. In particular he has been responsible for development of a global strategy to reduce child deaths from diarrheal diseases and other gastrointestinal disorders. This work has been funded by Bill Gates through his charitable trust, the Bill and Melinda Gates Foundation. He is also co-founder and Chairman of a charity (FMVSO) supporting a school and orphanage for destitute children in India. In the developed world, his work focuses mostly on finding solutions to the growing problem of antibiotic resistance.
Professor Chris G Dowson
Professor Chris G Dowson (School of Life Sciences, University of Warwick, UK) has, for many years, examined the emergence and evolution of antibiotic resistance across a wide range of bacteria. His recent focus has been to better understand how penicillin targets bacteria. This began during his postdoctoral time at the University of Sussex, in the laboratory of Professor Spratt (1986-1990) and subsequently with his Lister Institute Centenary Fellowship (1991-1996). He currently holds a personal chair at Warwick University and is a member of the Medical Research Council Infections and Immunity Board.
Chris’ research is highly collaborative, involving teams of biologists, chemists, engineers and physicists across universities in the UK, worldwide, and all importantly with industry, to help drive innovations from this research forward to a commercial outcome. He is involved with Antibiotic Discovery UK (AD-UK) and has been involved with research fundraising regionally across Warwickshire for the past 16 years with the Medical and Life Sciences Research Fund (MLSRF). He looks forward to brining all of this experience to help develop activities within Antibiotic Research UK (ANTRUK).
Partner, Ashurst LLPNick, a graduate of the University of Oxford, is a partner at international law firm, Ashurst LLP, based in the London office. Nick has over twelve years’ experience advising sponsors, commercial banks and funds on major infrastructure projects. He brings his strong, commercial background and experience to the Board of Trustees and, to the extent that the charity needs legal support in its day to day activities, he oversees advice provided by Ashurst on a pro bono basis. Nick has a long-standing interest in antibiotic resistance and has been involved with campaigns against the misuse of antibiotics in intensive livestock farming.
Professor Christine Bond
Professor of Primary Care and immediate past Head of Centre of Academic Primary Care, University of Aberdeen
From 1996-2012 Christine was part time Consultant in Pharmaceutical Public Health (NHS Grampian) where she established and chaired the Grampian Primary Care Antibiotic Strategy Group’. She has been awarded well over 100 grants (approximate total grant income >£13million) and has over 250 peer reviewed publications relating to a large portfolio of research on the evidence based cost effective use of medicines (prescribed and ‘OTC’), drug misuse, professional collaborations in primary care and the wider health care agenda. She is Editor of the International Journal of Pharmacy Practice, was an elected member of the Scottish Board of the Royal Pharmaceutical Society of Great Britain (RPSGB) for 10 years and has served on many national Research Panels eg the Health Service Research Committee of the Scottish Office, the MRC College of Experts, the Scottish Ethics Committee, the RPSGB Pharmacy Practice Research Trust Award panel, the Health Services and Pharmacy Practice Conference Panel. She is currently, a member of Pharmacy Research UK Steering Group, and Chair of the Royal Pharmaceutical Society of Great Britain Expert Advisory Panel for Science. In 2010 she was awarded the Pharma’s Lifetime Achievement Award.